Ignite Creation Date:
2025-12-25 @ 1:43 AM
Ignite Modification Date:
2026-05-08 @ 9:36 AM
Study NCT ID:
NCT04930094
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-31
First Post:
2021-06-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
Sponsor:
Novartis Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CAIN457R12301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None